ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

Yasmin Karimi

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Considering Alternatives to CAR-T in R/R DLBCL

Julio Chavez

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

Wojciech Jurczak

Tafasitamab/Lenalidomide for DLBCL: Which Patients and What to Expect

Amit Mehta